Equities

FunPep Co Ltd

4881:TYO

FunPep Co Ltd

Actions
  • Price (JPY)157.00
  • Today's Change0.00 / 0.00%
  • Shares traded26.00k
  • 1 Year change-15.14%
  • Beta1.4209
Data delayed at least 20 minutes, as of May 24 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FunPep Co Ltd is a Japan-based company engaged in the research and development business for pharmaceuticals. The main business is to promote research and development of functional peptides, which are the results of research at the Graduate School of Medicine, Osaka University, and to put them into practical use in the business fields such as pharmaceuticals, cosmetics and medical devices. The business model defines its technical area as a functional peptide-based area and a related area that has synergies with it. The Research & Development pipeline is composed of research themes for antibody-inducing peptides and developed products. The Company is engaged in the sale of peptide active ingredients through cosmetic raw material trading companies or sales companies.

  • Revenue in JPY (TTM)676.00k
  • Net income in JPY-760.40m
  • Incorporated2013
  • Employees15.00
  • Location
    FunPep Co Ltd3F, No.7 Mizuho Bldg., 5-8-4, SendagayaCHUO-KU 103-0023JapanJPN
  • Phone+81 353154200
  • Fax+81 353154203
  • Websitehttps://www.funpep.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Muromachi Chemicals Inc6.12bn216.69m3.01bn205.0013.751.398.570.491753.4553.451,503.34527.871.203.833.7529,862,370.004.23--6.84--28.31--3.54--1.4526.200.4483--10.74---43.83------
Ribomic Inc0.00-1.02bn3.07bn25.00--0.8917-----28.70-28.700.0094.200.00-------25.19-30.52-26.34-31.71-------1,777.8422.49-------100.00--38.04--4.42--
Atect Corp3.18bn-244.35m3.22bn96.00--1.829.321.01-55.27-55.27718.38398.840.58953.306.85---4.540.7132-6.410.971843.4047.04-7.691.320.6992--0.590284.767.231.45-253.71---23.490.00
Human Metabolome Technologies Inc1.34bn285.75m3.83bn57.0013.411.9910.362.8648.3148.31226.62326.170.564317.823.8023,500,000.0012.04--15.43--63.89--21.33--3.84124.760.1061--6.21--6.71------
Kubota Pharmaceutical Holdings Co Ltd39.74m-1.39bn3.94bn12.00--1.68--99.16-24.82-24.820.71141.580.01180.381526.893,312,000.00-41.32-36.51-45.53-39.4772.88---3,492.38-13,528.878.97--0.0555--383.24--26.11--24.38--
Kringle Pharma Inc77.93m-904.81m4.02bn13.00--1.71--51.53-159.92-159.9213.58356.640.027--2.805,994,308.00-31.29-19.00-33.20-20.23-----1,161.12-156.5112.85--0.00---82.33---157.41------
FunPep Co Ltd676.00k-760.40m4.08bn15.00--1.73--6,040.51-31.52-31.520.02890.560.0002--3.3945,066.67-26.86-27.10-28.42-28.75-----112,484.90-815.8217.27-1,006.150.00---50.33-72.8020.39---13.14--
BrightPath Biotherapeutics Co Ltd72.00k-1.17bn4.11bn32.00--4.19--57,147.16-18.30-18.300.001113.840.00005--2.36---79.69-51.56-87.69-54.3275.0068.63-1,622,336.00-22,321.82---435.390.1031---98.64-78.4721.37---46.55--
Perseus Proteomics Inc100.40m-1.10bn4.18bn24.00--2.73--41.60-93.74-93.748.52117.150.04713.358.55---51.85-41.34-54.94-43.4387.3391.72-1,100.04-891.2612.77------6.58-18.31-40.34--60.30--
Delta-Fly Pharma Inc0.00-1.43bn4.25bn11.00--3.45-----197.24-197.240.00149.780.00-------120.07-67.70-141.25-72.02-----------243.15---------7.57---9.04--
Renascience Inc194.17m-258.34m4.61bn3.00--2.87--23.77-20.32-20.3215.27126.400.089-------11.84---12.49--85.31---133.05------0.1814--93.11--23.07------
Immuno-Biological Laboratories Co., Ltd.816.70m186.69m4.65bn60.0024.893.67--5.6920.0520.0587.69135.860.5350.93584.53--12.23-13.9714.68-16.3963.3457.7322.86-39.233.65--0.1572--2.780.8924164.44------
Kidswell Bio Corp2.43bn-1.42bn4.84bn41.00--5.76--1.99-40.81-40.8168.7921.350.54151.842.47---31.67-57.41-51.25-81.1342.7555.20-58.49-123.521.70-28.910.7559---12.4318.93-116.31------
KAINOS Laboratories, Inc.5.06bn637.97m5.20bn144.007.480.76696.871.03152.41152.411,206.781,486.430.60533.084.55--7.646.929.969.2650.4651.8412.6210.802.43--0.122118.462.711.6012.2810.57-9.8316.36
Solasia Pharma KK408.00m-1.18bn5.22bn24.00--2.70--12.80-6.96-6.962.4010.010.14322.013.0617,000,000.00-41.50-48.57-53.67-58.8351.2371.01-289.71-300.891.68-400.000.2327---43.5014.1856.36------
OncoTherapy Science, Inc.610.12m-1.29bn5.27bn60.00--13.54--8.63-6.09-6.092.871.620.5139.087.69---108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
Data as of May 24 2024. Currency figures normalised to FunPep Co Ltd's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.